News of the FTC’s pending challenge to the Amgen deal sunk Horizon’s stock during early morning trading Tuesday, with the company’s shares down more than 17%.
(The Center Square) – The Federal Trade Commission said Tuesday it wants to block Amgen's $27.8 billion bid to acquire Horizon Therapeutics. Both companies said the deal would not raise competitive issues. .
The Federal Trade Commission said on Tuesday it will try to block an effort by biopharmaceutical leader Amgen Inc. from purchasing Horizon Therapeutics for $28.3 billion, charging the move could force insurance companies
The Federal Trade Commission has filed a lawsuit seeking to block biotechnology company Amgen from buying Horizon Therapeutics for $27.8 billion — the first time the FTC has tried to